Letter: Short-Term Effectiveness and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis in Real-World Clinical Practice
Dermatitis® · 01.11.2026 · 37 (6)
DOI: 10.1177/17103568261421387 ↗Kurz gefasst
Leserbrief in der Zeitschrift Dermatitis®, online erschienen am 20.03.2026. Verfasst von Rubén García Castro und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Dermatology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
- Department of Dermatology, Hospital Universitario Rey Juan Carlos, Madrid, Spain.
- Department of Dermatology, Hospital Universitario La Princesa, Madrid, Spain.
Zitieren
APA
García Castro, R., Sánchez Gilo, A., & Chicharro Manso, P. (2026). Letter: Short-Term Effectiveness and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis in Real-World Clinical Practice. Dermatitis®, 37(6). https://doi.org/10.1177/17103568261421387
Vancouver
García Castro R, Sánchez Gilo A, Chicharro Manso P. Letter: Short-Term Effectiveness and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis in Real-World Clinical Practice. Dermatitis®. 2026;37(6). doi:10.1177/17103568261421387
BibTeX
@article{GarcaCastro2026,
author = {García Castro, Rubén and Sánchez Gilo, Araceli and Chicharro Manso, Pablo},
title = {Letter: Short-Term Effectiveness and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis in Real-World Clinical Practice},
journal = {Dermatitis®},
year = {2026},
volume = {37},
number = {6},
doi = {10.1177/17103568261421387}
}
EUVIMED